N3538

Nateglinide

≥98% (HPLC), solid

• Synonym(s): Fastic, N-[(trans-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine, Starlix, Starsis
• Empirical Formula (Hill Notation): C₁₉H₂₇NO₃
• CAS Number: 105816-04-4
• Molecular Weight: 317.42
• NACRES: NA.77
• PubChem Substance ID: 329818636
• UNSPSC Code: 12352200
• MDL number: MFCD00875706
• Assay: ≥98% (HPLC)
• Form: solid

Properties

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: solid
• color: white to off-white
• solubility: DMSO: >5 mg/mL, H₂O: insoluble
• originator: Novartis
• storage temp.: room temp
• SMILES string: CC(C)[C@@H]1CC[C@H](CC1)C(=O)N[C@H](Cc2ccccc2)C(O)=O
• InChI: 1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1
• InChI key: OELFLUMRDSZNSF-BRWVUGGUSA-N
• Gene Information: human ... ABCC8(6833), KCNJ11(3767)

Description

Biochem/physiol Actions

Nateglinide is a K_ir6.2/SUR1 channel inhibitor and antidiabetic.

Nateglinide is a Kir6.2/SUR1 channel inhibitor and antidiabetic. It is selective for the SUR1 subtype, which is found on pancreatic islet cells. Nateglinide evokes KATP channel-dependent insulin secretion (50-200 μM) in the absence and presence of insulin.

Nateglinide is a short-acting insulin secretagogue useful in treating type 2 diabetes.[1] It is an insulinotropic agent effective for postprandial hyperglycemia. Nateglinide restores prandial insulin levels in a glucose-dependent manner.[2]

Features and Benefits

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Safety Information

• Storage Class: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)